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Orofacial manifestations occur frequently in rheumatic diseases and usually represent
early  signs of disease or of its activity that are still neglected in clinical practice. Among
the autoimmune rheumatic diseases with potential for oral manifestations, rheumatoid
arthritis (RA), inﬂammatory myopathies (IM), systemic sclerosis (SSc), systemic lupus ery-
thematosus (SLE), relapsing polychondritis (RP) and Sjögren’s syndrome (SS) can be cited.
Signs and symptoms such as oral hyposalivation, xerostomia, temporomandibular joint dis-
orders, lesions of the oral mucosa, periodontal disease, dysphagia, and dysphonia may be
the ﬁrst expression of these rheumatic diseases. This article reviews the main orofacial man-
ifestations of rheumatic diseases that may be of interest to the rheumatologist for diagnosis
and  monitoring of autoimmune rheumatic diseases.
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
O  que  o  reumatologista  deve  saber  sobre  as  manifestac¸ões  orofaciais
das  doenc¸as reumáticas  autoimunes
alavras-chave:
r  e  s  u  m  o
Manifestac¸ões orofaciais ocorrem com frequência nas doenc¸as reumáticas e, comumente,iniciais ou de atividade da doenc¸a que ainda são negligenciados naoenc¸as reumáticas autoimunes representam sinais 
anifestac¸ões orofaciais
aliva
esões bucais
oenc¸a periodontal
prática clínica. Entre as doenc¸as reumáticas autoimunes com possíveis manifestac¸ões orais,
incluem-se a artrite reumatoide (AR), miopatias inﬂamatórias (MI), esclerose sistêmica
(ES), lúpus eritematoso sistêmico (LES), policondrite recidivante (PR) e síndrome de Sjö-
gren (SS). Sinais e sintomas orofaciais como hipossalivac¸ão, xerostomia, disfunc¸ões
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temporomandibulares, lesões na mucosa bucal, doenc¸a periodontal, disfagia e disfo-
nia podem ser a primeira expressão dessas doenc¸as reumáticas. Esse artigo revisa as
principais manifestac¸ões orofaciais das doenc¸as reumáticas que podem ser de inter-
esse  do reumatologista, para diagnóstico e acompanhamento das doenc¸as reumáticas
autoimunes.
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC
muscles. Imaging studies may show bone structure loss atIntroduction
Autoimmune rheumatic diseases constitute a heterogeneous
group of conditions characterized by immune tolerance
breakdown and production of autoantibodies and of a num-
ber of substances responsible for lesions in several body
structures. In this category, rheumatoid arthritis (RA), inﬂam-
matory myopathies (IM), systemic sclerosis (SSc), systemic
lupus erythematosus (SLE) and Sjögren’s syndrome (SS) can
be included.1
Some rheumatic diseases show mucocutaneous manifes-
tations. Generally, the changes are consequences of systemic
disorders and manifest themselves insidiously, showing signs
and symptoms in the oral cavity (Table 1). However, in the con-
text of autoimmune diseases, the oral approach appears to
have not yet aroused scientiﬁc interest. In this paper, some
dental clinical ﬁndings often found in patients treated at the
Rheumatology Outpatient Clinic of Brasília, Hospital Univer-
sitário de Brasilia (HUB)–UNB will be discussed, based on a
narrative literature review. For this review, the following terms
were entered in PubMed database (Autoimmune Rheumatic
Disease [all ﬁelds]) AND “dentistry” [all ﬁelds], limited to those
studies conducted on human subjects. It was found that are
only sixty-eight studies were published until June 21, 2015.
Some studies point to epidemiological data of medical and
dental interest. In this context, clearly one realizes the limited
approach to the subject. However, the papers chosen demon-
strate that the dentist can and should act in the early diagnosis
and management of these disorders, since these patients have
speciﬁc needs.
Thus, this narrative review aims to address the main orof-
acial manifestations in autoimmune rheumatic diseases that
may be of interest to the rheumatologist for diagnosis and
clinical follow-up.
Literature  review
Rheumatoid  arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune inﬂam-
matory disease of unknown etiology.2 The classic features of
this disease are chronic, bilateral and symmetric polyarthri-
tis, joint pain and inﬂammation that can result in deformity,
instability and destruction of synovial joints.3,4 RA affects
more  often the synovial membrane of small joints of the
extremities, resulting in swelling, edema and pain, and can
lead to bone and cartilage destruction, severe disability and
untimely mortality.3BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The most common oral manifestations in patients with RA
are:
Temporomandibular  disorder  (TMD)
The temporomandibular joint (TMJ) is a synovial joint and
can be affected by disorders in non-articular tissues, with
manifestations of muscle spasm, ﬁbromyalgia, and myotonic
dystrophy, among others. However, TMJ  joint tissues may also
be affected by mechanical trauma, infection, iatrogenic disor-
ders, and gout, as well as by autoimmune rheumatic diseases
such as RA and psoriasis.5 One can observe the presence of
typical inﬂammatory mediators of osteoarthritis, including
tumor necrosis factor (TNF)-,  interleukin (IL)-1, IL-6 and IL-
8. These ﬁndings maintain correlation with the extent of the
disease, i.e., clinical symptoms, number of joint effusions or
morphological changes.6,7
TMDs are considered to be the most common conditions
causing orofacial pain of non-dental origin, and the dentist
is the professional responsible for the clinical examination
of TMJ and for requesting imaging exams of this anatomi-
cal region. A TMD can manifest symptoms such as ear pain,
headache, non-speciﬁc nerve pain, and toothache. Its diagno-
sis requires a medical and dental approach, which makes the
evaluation of the prevalence of TMD a complex issue, and its
study is often overlooked in the clinical practice of rheumatic
autoimmune diseases.8,9
TMD can occur both in adults and – more  commonly –
in children with RA. A study that evaluated 223 children
with juvenile idiopathic arthritis revealed that 38.6% had
some TMJ involvement (pain, swelling and/or limitation in
range of motion).10 When TMJ involvement is manifested
during a child’s development, there may be a mandibu-
lar growth restriction, resulting in micrognatia and/or
ankylosis.11
In adults, studies on the prevalence of TMD  in RA patients
resulted in extremely varied values (5–86%), depending on the
population studied, diagnostic criteria used, and assessment
methods.4,5 TMD  is the most common orofacial manifestation
in RA patients. The patient may show a bilateral, profound
and pervasive acute pain, which is exacerbated during the
function. The clinical examination may reveal: malocclusion,
sensitivity and inﬂammation of pre-auricular regions, joint
stiffness upon waking, limitation of jaw movement, intracap-
sular crepitus or clicking and pain in masticatory and/or neck
4,12the condylar head (Fig. 1). The occurrence of TMJ  ankylosis is
quite unusual, becomes evident only at a late stage, and may
be bilateral.4,13
r e v b r a s r e u m a t o l . 2 0 1 6;5 6(5):441–450 443
Table 1 – Oral manifestations of autoimmune rheumatic diseases and their clinical implications.
Oral events Autoimmune rheumatic diseases
RA IM SSc SLE SS Clinical implications
PM DM
Periodontal disease X X X • Worsening factor for diabetes and rheumatic
and heart diseases
Dental caries X X X • Depending on the extent of the injury, pain,
chewing involvement, and foci of infection can
occur, likely worsening diabetes and rheumatic
and heart diseases
Candidiasis X X • Itching and/or burning in the mucosa
• Risk of esophageal infection
• Inappetence
Hyposalivation X X X X • Dysphonia
• Dysphagia
• Thrush and ulcers in the oral mucosa
• Greater tendency to oral and oropharyngeal
infections30
• Recurrent esophagitis
• Sleep interrupted for water intake and
urination
Xerostomia X X X X X • Decrease in quality of life
Halitosis X • Decrease in quality of life
Mouth burning X X X X • Dysgeusia
• Eating difﬁculty
• Cancer phobia
Oral ulcers X X X • Pain
• Difﬁculty in feeding and oral hygiene
TMD X X X X • Headache
• Otalgia and/or tinnitus
• A feeling of ear tamponade
• An irradiating cervical pain
• Chronic headache
• Limited mouth opening
• Difﬁculty to chew and speak12
Microstomia X • Limited mouth opening
• Difﬁculty in eating and to have a good oral
hygiene46
Regional resorption of
jaw bone/TMJ
X  • Limited mouth opening
Dysphagia X X X • Dehydration
• Malnutrition
Aspiration of secretions and/or food to the
lung–aspiration pneumonia
Dysphonia X X X X • Decrease in quality of life
Changes in language X X X • Difﬁculty to perceive food, speech and
swallowing.
Angle cheilitis X • Pain and limited mouth opening
Alterations in tooth
morphology
X  • Facial esthetics and masticatory function
changes
Pathological changes in
salivary glands
X  X • Hyposalivation
Changes in mimic and
chewing muscles and
in the pharynx
X  • Dysphagia
• Dysphonia
• Difﬁculty to chew
Trigeminal neuralgia • Episodes of intense pain in the eyes, lips, nose,
scalp, forehead and/or jaw
DM, dermatomyositis; IM, inﬂammatory myopathies; PM, polymyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus;; SSc,
systemic sclerosis; SS, Sjögren’s syndrome; TMD, temporomandibular dysfunction.
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Fig. 1 – Computed tomography of temporomandibular joint of a patient with rheumatoid arthritis and complaint of clicking
rtio
inenwhile chewing. Presence of subchondral cyst in the upper po
of the left mandibular head (b) and ﬂattening of articular em
Periodontal  disease  (PD)
PD is a chronic infectious disease caused by Gram-negative
anaerobic bacteria, affecting the tissues of protection and
support of the tooth, such as gums, periodontal ligament,
cementum and alveolar bone. Under PD designation, both
reversible (gingivitis) and irreversible (periodontitis) processes
are included. When undiagnosed and untreated, PD can cause
progressive destruction of alveolar bone, causing tooth mobil-
ity and subsequent dental loss.14 According to the World
Health Organization, periodontal disease affects approxi-
mately 10–15% of the world population.14 Brazilian ofﬁcial
data show that 19.4% of adults aged 35–44 years are carriers
of this disease.15
Some recent studies also suggest a signiﬁcant association
between RA and PD.13,16–18 The relationship between RA and
progression of inﬂammatory conditions (p.ex., periodontitis)
is not clear. The main reason for this scenario is the lack of
uniformity in the classiﬁcation of the various forms of both
diseases.19 It is estimated that the prevalence of PD increases
twice in RA patients compared to the general population.17
Thus, the presence of a moderate-to-severe RA also increases
more  than twice the risk of developing forms of moderate-
to-severe periodontitis compared to individuals without the
disease.17–19
Furthermore, there is evidence of similarity in the patho-
genesis of RA and PD. Microorganisms such as Porphyromonas
gingivalis may play a role in both conditions,16 being able to
invade isolated human chondrocytes in the knee joint, inter-
fering with cell cycle and inducing these cells’ apoptosis.20n of the right mandibular head (a), erosion of lateral portion
ces (c).
Another important factor would be that P. gingivalis expresses
the peptide arginine deiminase (PAD), which converts argi-
nine to citrulline by a citrullination process. This process,
which is common to some human proteins, is associated
with the pathophysiology of RA. It has a low immune toler-
ance to citrullinated proteins in synovial ﬂuid, which triggers
the development of immunoglobulins against these proteins,
present in joints and tendons.21,22 In addition, studies have
demonstrated the presence of antibodies in response to oral
anaerobic bacteria in the synovial tissue and serum. Others
authors also found the presence of oral bacterial DNA in the
synovial ﬂuid of RA patients.18 In fact, RA and PD have a vari-
ety of markedly similar clinical and pathophysiologic features
(Table 2).23,24
Although periodontal disease has local clinical manifes-
tations, its chronic inﬂammatory nature can contribute to
change – and even worsen – the course of RA and of other
rheumatic diseases. A recent systematic review by Kaur et al.
(2013) demonstrated a good level of evidence to support an
association between RA and PD, taking into account tooth loss,
the clinical attachment level, and erythrocyte sedimentation
rates. Moderate evidence was noted in C-reactive protein and
interleukin-1 values. A positive outcome of periodontal treat-
ment was observed, with respect to the clinical features of
RA. However, more  studies are needed to fully explore the
biochemical processes and the relationship between these
chronic inﬂammatory diseases, despite the similarity in the
pathophysiologic characteristics of RA and PD. It is found that
six months after the completion of periodontal therapy, the
improvement of oral health is strongly associated with an
r e v b r a s r e u m a t o l . 2 0 1
Table 2 – Pathophysiological similarities in the
characteristics of rheumatoid arthritis and periodontal
disease.23,24
Pathophysiological
characteristics
RA  PD
Cell inﬁltrate Macrophages, T
lymphocytes,
plasma cells and
PMN
Equivalent
Immune
phenomenon
Immune complex
deposition,
complement
ﬁxation
Equivalent
Cytokines IL-1,  IL-1,  IL-6,
IL-8, TNF- and
TGF-
Equivalent
Local cells affected Chondrocytes and
synoviocytes
Gingival
ﬁbroblast,
osteoblast, and
keratinocytes
Induction of bone
resorption
PGE2, TNF-,  IL-1  LPS, PGE 2,
TNF-, IL-1
Tissue Destruction Metalloproteinase,
phospholipase
and elastase
Equivalent
Granulation tissue Present in
cartilage/bone
interface
Present in the
cement/bone
interface
IL-1,  interleukin-1 alpha; IL-1,  interleukin-1 beta; IL-6,
interleukin-6; IL-8, interleukin-8; LPS, lipopolysaccharide; PD,
periodontal disease; PGE2, prostaglandin E2; PMN, polymorphonu-
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tclear leukocytes; RA, rheumatoid arthritis;TNF-,  tumor necrosis
factor alpha; TGF-,  growth transforming factor beta.
mprovement in endothelial function, with a decrease in local
nd systemic inﬂammatory processes.25
yposalivation/xerostomia
mong oral changes, it turns out that hyposalivation (low
alivary ﬂow)  and xerostomia (dry mouth) are common in
utoimmune rheumatic diseases, and xerostomia affects 1%
f RA patients.26 About one third of RA patients have sec-
ndary SS.27 A study including 604 RA patients showed a
ecrease in salivary ﬂow in 43% of subjects.28 The risk of
eveloping hyposalivation increases with the severity of the
isease. It is worth mentioning that another study conducted
n 483 hospitalized patients due to complications of arthritis
ound that only 17.7% of xerostomia-positive patients were
reated for xerostomia. In contrast, 84.8% of patients treated
or xerophthalmia were treated for this condition. It was also
bserved that the therapeutic modalities administered for
erostomia were not effective and also were not in accor-
ance with current recommendations found in the medical
29iterature.
Therefore, a timely diagnosis and proper monitoring of SS
ssociated with RA are important steps to promote gains in
he quality of life of these patients (as will be discussed in the 6;5 6(5):441–450 445
SS section), taking into account that saliva performs functions
of systemic interest, for instance, the sense of taste, epithe-
lial repair of oropharynx and esophagus, and esophageal acid
content buffering, among other functions.30
Inﬂammatory  myopathies
Polymyositis (PM) and dermatomyositis (DM) are autoimmune
diseases classiﬁed as idiopathic inﬂammatory myopathies,
being characterized by musculoskeletal inﬂammation.31
PM is a systemic connective tissue disease, characterized by
bilateral, symmetrical, proximal muscle weakness. It affects
muscles of the shoulder and pelvic girdle and progresses
toward proximal muscles of the limbs. Its onset is frequently
gradual and progressive. PM exhibits a geographically variable
incidence, with about one case for every 100,000 inhabitants,
predominantly affecting females.32
Impairment of skeletal muscles of posterior pharyngeal
wall and proximal third of the esophagus can lead to
oropharyngeal dysphagia, with aspiration and dysphonia.
Consequently, the patient can complain of hypersalivation.
This complication, however, will be due to an impaired func-
tional activity of swallowing muscles in association with the
salivary reﬂex caused by reﬂux. Two thirds of the patients
present involvement of the neck ﬂexor muscles, which can
cause difﬁculty in neck support. Constitutional symptoms
include fatigue, low-grade fever, weight loss, and arthralgia
or arthritis of small and medium joints.33
Some rare case reports relate presence of ulcerations on the
entire tongue, of a linear aspect and with a white secretion on
the edges, and also tongue atrophy, in which one can observe
a reddened mucosa.34
DM is an autoimmune disease of unknown etiology that
is characterized by a systemic small-vessel vasculopathy
predominantly involving muscles and skin. Besides the cuta-
neous involvement, the characterization of DM is based in the
pattern of muscle involvement, presence of associated clinical
manifestations, and histopathological changes.35
The prevalence of oral involvement in DM is unknown.
Most of the information available comes from individual case
reports or small case series, and some early reports of cases
did not clearly separate MS from PM.36
An involvement of mimic  muscles may occur, which leads
to a decrease in facial expression. Similarly, the involvement
of the masticatory and pharyngeal muscles may result in dys-
phagia, dysphonia, and hypersalivation. The involvement of
striated muscle of the pharynx or esophagus also contributes
to the occurrence of dysphagia. In patients with dysphagia,
DM reaches 18–50% of patients and correlates with disease
severity.36,37 In addition, the presence of dysphagia increases
the risk of aspiration pneumonia. Mortality rates range from 1
to 5 years, reaching 31% of patients with DM and dysphagia.37
However, the occurrence of hypersalivation is not always
attributable to an excess in saliva production, but may be
caused by an inability to retain saliva and swallowing it, due to
the weakness of perioral muscle tone, or because of dysphagia.
The involvement of tongue muscle results in macroglossia,
in addition of hypotonia, which can also make it more  difﬁ-
cult chewing, swallowing and speech.38 Involvement of the
mucous membrane is reported in about 10–20% of cases.39
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Mucosal edema, erythema and telangiectasia are the com-
monest oral changes.38
Although 27.5% of patients with DM also suffer arthritis,
TMJ  involvement is rare, with only one case reported in the
literature. In some reports, the presence of prominent blood
vessels throughout the oral mucosa and aphthous stomatitis/
ulcer-like lesions were described.40 About 10–46% of patients
develop painful oral and gingival ulcers.41 The teeth have short
and bulging roots, with obliteration of root canals as well as
pulp chamber calciﬁcation. Xerostomia is also seen as a com-
mon  complaint.42
Systemic  sclerosis
Systemic sclerosis (SSc) is an autoimmune disease charac-
terized by inﬂammation and hyper-reactivity of micro- and
macrovascular circulation associated with excessive collagen
deposition in tissues, with subsequent ﬁbrosis of the skin
and/or internal organs.43 SSc has a predilection for females,
with an incidence of 2–10/one million inhabitants in the gen-
eral population.44 In addition, there is a consensus about an
increase in morbidity and mortality, with an estimated 66%
survival at 10 years.45
The oral manifestations are scarcely studied and often
neglected by clinicians, although leading to major functional
disability. Microstomia is the most common oral ﬁnding and
develops due to collagen deposition in perioral tissues, caus-
ing limitation of mouth opening, perioral groove wrinkling,
and soft palate, larynx and oral mucosa stiffness.46 Fur-
thermore, hyposalivation and/or dry mouth are secondary
manifestations of the disease. TMD  can also occur, with vary-
ing degrees of subsequent resorption of mandibular branch,
coronoid process, menton and condyle.5 It is believed that
these areas are reabsorbed due to the chronic collagen
deposition. Tongue cancer has a signiﬁcantly increased fre-
quency in patients with SSc that present a mouth opening
<30 mm.47
The resorption of some teeth has also been reported with
some frequency in these patients. There may be an abnor-
mal  increase in the frequency of decayed teeth and of an
Fig. 2 – Patient with systemic lupus erythematosus with gingiva
disease with extensive loss of attached gingiva (a) and regions w
lichen planus reticular with gingival (c) and mucosal (d) Wickham
rheumatologist, suspecting that the lupus was active; this suspic 0 1 6;5 6(5):441–450
atypical tooth eruption. Apparently there is also a predis-
position for the occurrence of PD, due to increased plaque
buildup. This problem arises from the difﬁculty of cleaning the
mouth (caused by a smaller mouth opening) and in the use
of the dental brush. This latter complication is due to scle-
rotic changes in ﬁngers and hands. Furthermore, the use of
systemic corticosteroids for long periods inﬂuence in reduc-
ing the periodontal inﬂammatory response, thus making this
process a progressive and often insidious one.48
Systemic  lupus  erythematous
SLE is an autoimmune disease of unknown etiology, inﬂu-
enced by environmental and genetic factors, and which
mainly affects women in the second and third decades of
life.49 The prevalence of oral lesions in patients with SLE
varies between 6.5% and 21%. SLE affects primarily tongue,
oral mucosa, lips and palate. For this reason, oral ulcers are
considered primary events, that are included in the follow-
ing activity indexes of this disease: BILAG (British Isles Lupus
Assessment Group),50 SLEDAI (Systemic Lupus Erythematosus
Disease Activity Index),51 SELENA-SLEDAI (Safety of Estro-
gens in Lupus Erythematosus National Assessment), SLAM
(Systemic Lupus Activity Measure),52 and ECLAM (European
Consensus Lupus Activity Measurement).53
The lesions appear in different ways, such as blemishes
and plaques on the mucosa. The lesions may be erythe-
matous, ulcerated, of a recurrent aphthous stomatitis, and
lichen planus- or leukoplakia-like lesions (Fig. 2). The size of
these lesions is also variable, from a small surface erosion
to ulcers covering a wide and extensive area.54,55 The few
studies on oral lesions in patients with SLE show, microscop-
ically, parakeratosis or orthokeratosis, acanthosis, epithelial
atrophy, vacuolar degeneration of the basal membrane with
necrosis of basal keratinocytes, basement membrane thick-
ening, lichenoid mononuclear inﬁltrate, and deep connective
tissue vasculitis. Injuries in the vermilion border of lips (espe-
cially in the lower lip), deserve special attention, as these
lesions may be related to lupus cheilitis, with or without
epithelial dysplasia.54,56
l and tooth sensitivity complaint. Presence of periodontal
ith a purulent exudate (b). There is a manifestation of
 striae. The dentist referred this patient to the
ion was subsequently conﬁrmed.
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Other secondary orofacial signs/symptoms include: mouth
urning, hyposalivation, xerostomia, salivary gland disease
such as focal necrosis of the parotid gland), TMD, desqua-
ative gingivitis and PD.54 Hyposalivation can lead to an
ncreased occurrence of dental caries and to a predisposition
o candidiasis, especially if immunosuppressive agents such
s corticosteroids are being used.56
jögren’s  syndrome  (SS)
S is an inﬂammatory autoimmune disease presenting a fre-
uent chronic course, in which the lymphocytic inﬁltration
f exocrine glands, particularly lacrimal and salivary glands,
mpairs its secretory function.55 Simultaneously, systemic
anifestations of cutaneous, respiratory, renal, hepatic, neu-
ologic and vascular nature can occur. SS has two distinct
orms: primary SS – not associated with another disorder; and
econdary SS – in which the patient expresses this syndrome
n association with other autoimmune diseases.57,58
It is estimated that SS affects 0.2% of the world popula-
ion, mainly women, in a ratio of 9:1.57,58 In Brazil, due to the
bsence of ofﬁcial estimates or scientiﬁcally conﬁrmed data
n its incidence, no one knows the exact number of patients
ith this syndrome. However, it was stated that the majority of
iagnosed cases are related to menopausal, or older, women.59
SS follows a variable course and exhibits a wide spectrum
f clinical manifestations. In addition, many  of its symptoms
re non-speciﬁc, making difﬁcult and delaying the diagnosis.
ighty percent of patients with SS exhibit an insidious onset of
ymptoms of dryness that develop over a period from several
onths to years.58
The oral manifestations observed in patients with SS are
ttributed to the involvement of salivary glands, which leads
o less salivary secretion. In consequence, the worse lubrica-
ion and loss of buffering and antimicrobial action of salivary
ecretion increase the incidence of oral/dental infections,
ucosal friability, and symptoms of irritation and burning
outh (Fig. 3).57 On the other hand, some patients complain
f xerostomia, which may not be accompanied by a decrease
n salivary secretion.30 However, in the initial stage of the
isease, when the diagnosis has not yet been well estab-
ished, patients may complain of xerostomia due to changes in
ig. 3 – Loss of papillae of the tongue(a) and candidiasis (b) in a p
omplaints of a burning mouth, feeling of “something stuck in th
alivary patterns showed severe hyposalivation (unstimulated sa
nd an acidic pH (6.3). Loss of mineral structure with clefts forma
romote great discomfort to the patient, because of the greater a 6;5 6(5):441–450 447
salivary composition, or to a reduction of salivary secretion
from the smaller salivary glands (from lip mucosa and palate).
Thus, sialometry may reveal that the patient has a normal
salivary ﬂow; however, salivary composition tests will indicate
qualitative changes.60
Usually, dental caries and fungal infections are observed in
mucous membranes (especially candidiasis) that can manifest
as pseudomembranous or erythematous lesions. The friability
of the mucosa in patients with SS often leads to soft tis-
sue injuries. Such signs include dry and cracked lips, median
rhomboid glossitis or a ﬁssured tongue, loss of lingual papil-
lae, stomatitis, angular cheilitis, aphthous injury, lip mucosal
ulcers, difﬁculty in swallowing solids, and odynophagia.57
SS patients often display voice disorders and correlated
symptoms that are associated with a decrease in their quality
of life. It is known that the lubrication of the vocal cords is
carried out by saliva.61 Thus, this biological ﬂuid is important
for a proper phonation.
Another relevant point refers to the drop in the quality
of life of patients with SS, because of their changing eating
habits, caused by dry mouth.62 There is a Strong correlation
among oral dryness and fatigue, pain, psychological distress,
and a worse quality of sleep; and that it is considered as a car-
diovascular risk factor.63 In this study, the authors concluded
that a multidisciplinary therapeutic approach may be the best
way to minimize dry mouth and its consequences in patients
with primary SS.63
Finally, another common oral manifestation is an asymp-
tomatic and self-limiting increases of parotid glands or other
major salivary glands,55 which may be pointing to the early
stage of SS.
Therefore, the establishment of an early diagnosis of SS is
essential for the choice of the correct treatment, which con-
sists in relieving the signs and symptoms in order to minimize
or avoid sequels that can impact on the health and quality of
life of patients.64
Gustatory, mechanical and chemical sialogogues have been
used to stimulate saliva production. However, the effective-
ness of these resources is low, because they provide only
temporary relief, requiring frequent applications.65 Many  top-
ical treatments such as sprays, lozenges, mouthwashes, gels,
oils or toothpastes have been evaluated, but there is no strong
atient with Sjögren’s syndrome who presented with
e throat” and reduced sense of taste. Examinations of
livary ﬂow rate: 0 ml/min; ﬂow with stimulus: 0.1 ml/min)
tion in teeth (c) and resin porosity (d), conditions that
ttrition with the dried up mucosa.
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evidence that any of these topical treatments is effective to
alleviate the patient with dry mouth.66 Oxygenated tri-ester
glycerol-based lubricants are more  effective than water-based
electrolyte sprays. Chewing gum increases saliva production,
but there is no evidence that these products are better or worse
than saliva substitutes. However, acidic secretagogues and
those containing sugar should be avoided,66 because these
products lower oral pH, promote greater tooth demineraliza-
tion and irritate a mucous already very sensitive. One should
opt for the use of sugar-free chewing gum, but containing ﬂu-
oride and bicarbonate in its composition. These components
increase salivary pH and assist in preventing tooth decay.67,68
Chemical sialagogues, such as pilocarpine and cevime-
line, are effective in relieving hyposalivation, but may cause
adverse effects.65 Electrical stimulation applied to the affer-
ent pathways (through the oral mucosa or skin) in areas of
salivary glands, showed increased saliva production and relief
of dry mouth in patients with SS65 and in patients undergoing
cervical-brain radiotherapy.69
A systematic review of randomized controlled trials was
conducted to gather evidence on drug therapy in primary SS.
The authors suggested that saliva substitutes and sugar-free
chewing gums may be effective in cases of mild-to-moderate
dry mouth. Consumption of alcohol and smoking should be
avoided, and it is a critical factor the establishment of a
thorough oral hygiene. The treatment of choice for patients
with residual function of salivary glands is cevimeline and
oral pilocarpine. However, no study was published compar-
ing the efﬁcacy of these two drugs. The doses which have
shown better effects in terms of efﬁcacy and safety were:
pilocarpine 5 mg  every 6 h; and cevimeline 30 mg  every 8 h.
N-acetylcysteine could be an alternative in patients with con-
traindications or intolerance to muscarinic agonists.70
Conclusion
Orofacial manifestations in patients with autoimmune
rheumatic diseases are common problems, but still sparsely
addressed by rheumatologists in their everyday clinical
practice. This article produced a summary of the main mani-
festations observed, in order to familiarize these professionals
with their diagnoses, underlying the possible need for an early
referral to the dentist.
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